Q2 Earnings Round-Up Part 1: Signs Of Pandemic Recovery
Small-to-medium-sized companies launching their first or one of their only commercial products faced a particular difficult time during the pandemic. In the second quarter earnings calls, some of these SMEs are seeing momentum as the most serious COVID headwinds resolve but others are contending with ongoing challenges. [Check back tomorrow for Part 2 on companies experiencing continuing challenges.]
You may also be interested in...
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.